![]() | |
Clinical data | |
---|---|
Other names | BPI16350 |
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C28H32F2N8 |
Molar mass | 518.617 g·mol−1 |
BPI-16350 is a small molecule CDK4/6 inhibitor that is being studied for the treatment of cancer. [1] [2] It has a similar structure to abemaciclib but is more selective for CDK4/6 over CDK9 according to preclinical research. [3]
{{
cite journal}}
: Cite journal requires |journal=
(
help)
![]() | |
Clinical data | |
---|---|
Other names | BPI16350 |
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C28H32F2N8 |
Molar mass | 518.617 g·mol−1 |
BPI-16350 is a small molecule CDK4/6 inhibitor that is being studied for the treatment of cancer. [1] [2] It has a similar structure to abemaciclib but is more selective for CDK4/6 over CDK9 according to preclinical research. [3]
{{
cite journal}}
: Cite journal requires |journal=
(
help)